^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Endometrial Cancer
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

    Excerpt:
    ...- For Cohorts 2, 3, 4, 5, 6 documented HER2 amplification identified through next generation sequencing by MSK-IMPACT or at another Clinical Laboratory Improvement Amendments (CLIA) laboratory, or documented HER2 amplification by in-situ hybridization (ISH) with HER2/CEP17 ratio ≥2.0 at a CLIA laboratory....
    Trial ID:
    NCT02675829
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

    Published date:
    05/16/2018
    Excerpt:
    Ado-trastuzumab emtansine showed efficacy in patients with HER2 amplified lung, endometrial, salivary gland, biliary tract and ovarian cancers as identified by NGS.
    DOI:
    10.1200/JCO.2018.36.15_suppl.2502
    Trial ID:
    NCT02675829